Abstract: The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.
Abstract: The invention relates to an in vitro method for determining procalcitonin levels in plasma and urine as a diagnostic marker to identify patients with urinary tract infections, in vitro methods to perform said determination, a kit for the diagnosis of patients with urinary tract infections, and the usefulness of procalcitonin in the diagnosis urinary tract infections.
Type:
Application
Filed:
May 1, 2014
Publication date:
August 28, 2014
Applicant:
B.R.A.H.M.S. GMBH
Inventors:
Francesco GIUNTA, Francesco FORFORI, Giada SERI
Abstract: The present invention relates to a method for the diagnosis, prognosis, monitoring and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in a patient comprising the steps of: providing a sample of a bodily fluid of a patient; determining the level of proSomatostatin 1-64 or fragments thereof in said sample; correlating the level of proSomatostatin 1-64 or fragments thereof to the diagnosis, prognosis and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in said patient, wherein said fragments have a length of at least 6 amino acid residues. The invention also relates to an antibody and a kit containing at least two antibodies.
Abstract: The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues.
Type:
Application
Filed:
July 2, 2012
Publication date:
June 19, 2014
Applicants:
B.R.A.H.M.S. GMBH, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
Abstract: The invention relates to an in vitro method for determining procalcitonin levels in plasma and urine as a diagnostic marker to identify patients with urinary tract infections, in vitro methods to perform said determination, a kit for the diagnosis of patients with urinary tract infections, and the usefulness of procalcitonin in the diagnosis urinary tract infections.
Type:
Grant
Filed:
March 15, 2011
Date of Patent:
June 10, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Francesco Giunta, Francesco Forfori, Giada Seri
Abstract: An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.
Type:
Grant
Filed:
August 1, 2008
Date of Patent:
May 27, 2014
Assignee:
B.R.A.H.M.S GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler, Jana Papassotiriou, Stefan Blankenberg, Karl Lackner, Hans Rupprecht, Christoph Bickel
Abstract: The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps: a) Preparation of a reversible binding partner 1 that is immobilized on a solid phase, to which an analyte binder is reversibly bonded via a reversible binding partner 2 that is bonded to the analyte binder, whereby the analyte binder is immobilized by binding between the reversible binding partners 1 and 2, b) Addition of the biological sample and binding of the analyte to the reversible immobilized analyte binder in the case that the biological sample contains the analytes, c) Separation of the biological sample, d) Addition of a dissolving buffer, which dissolves the binding between the reversible binding partners 1 and 2, whereby the binding of the analyte to the analyte binder remains optional, and e) Detection of the analyte in the dissolving buffer in the case that the biological sample contains the analytes and determination of the absence of the analyte in the case t
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
April 8, 2010
Date of Patent:
April 8, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: Subject of the present invention is a method of assessing the susceptibility of a subject to acquire cancer and/or assessing the risk of cancer mortality for a subject, who has not had clinically manifest cancer and/or does not have clinically manifest cancer at the time when applying this method.
Type:
Application
Filed:
June 17, 2011
Publication date:
February 20, 2014
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Andreas Bergmann, Joachim Struck, Olle Melander
Abstract: The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANp or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention.
Type:
Grant
Filed:
May 6, 2008
Date of Patent:
February 11, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Jana Papassotiriou, Joachim Struck, Nils Morgenthaler, Stefan Anker
Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting to the emergency department with non-specific complaints.
Type:
Application
Filed:
October 31, 2011
Publication date:
November 14, 2013
Applicant:
B.R.A.H.M.S GMBH
Inventors:
Joachim Struck, Sven Giersdorf, Oliver Hartmann, Roland Bingisser, Christian Nickel
Abstract: The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.
Type:
Grant
Filed:
December 22, 2007
Date of Patent:
September 3, 2013
Assignee:
B.R.A.H.M.S GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Abstract: The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea.
Abstract: The present invention relates to the use of affinity-purified polyclonal human autoantibodies against the TSH receptor (TSHR-Auto-Ab), obtained from the serum of Graves' disease patients and which have been purified to obtain biochemical homogeneity and comprise a specific activity of at least 1 IU/mg protein (human immunoglobulin). Also disclosed is the use of animal antibodies, which compete with the former for the binding sites of a functional human TSH receptor, as a specific binding reagent in an immunological determination method for the clinical identification of autoantibodies against the TSH receptor (TSHR-Auto-Ab) in a sample of a biological fluid of a patient to be examined for Graves' disease.
Type:
Grant
Filed:
October 31, 2003
Date of Patent:
August 6, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Sabine Costagliola, Gilbert Vassart
Abstract: The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
Type:
Grant
Filed:
October 26, 2007
Date of Patent:
August 6, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Abstract: The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method.
Type:
Grant
Filed:
October 1, 2007
Date of Patent:
June 18, 2013
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck
Abstract: Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.
Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116.